CALC
$0.83
Market ClosedAs of Mar 17, 8:00 PM UTC
CalciMedica, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage.
Recent News
CalciMedica’s stock drops 75% on acute kidney injury trial termination
The biopharma will now evaluate how it can safely progress Auxora’s development in AKI.
CalciMedica Insiders Added US$1.05m Of Stock To Their Holdings
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...